Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen (NASDAQ:RGEN) will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. A press release will be issued before market open and management will host a conference call at 8:30 a.m. ET to discuss results for periods ended December 31, 2025.
The live call is toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode. A webcast and subsequent replay will be available in the company Investor Relations section of the website.
Details
News Market Reaction – RGEN
On Feb 10, the day this news came out, RGEN closed 0.36% below the previous close.
Data tracked by StockTitan Argus for the Feb 10 session.
Key Figures
- Earnings date
- February 24, 2026
- Fourth quarter and full year 2025 results release and call
- Earnings call time
- 8:30 a.m. ET
- Start time for Q4 and full-year 2025 conference call
- Reporting periods
- Three- and twelve-month
- Periods ended December 31, 2025 to be discussed
- Domestic dial-in
- (800) 715-9871
- Toll-free number for U.S. callers to access the earnings call
- International dial-in
- (646) 307-1963
- Number for international callers to access the earnings call
Historical Context
-
Announcement of chair transition and advisor role through March 2027.
-
Presentation scheduled at J.P. Morgan 2026 Healthcare Conference.
-
Introduction of three new chromatography resins for next‑gen modalities.
-
Planned participation in 8th Annual Evercore Healthcare Conference.
-
Series of November 2025 investor conference appearances with webcasts.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2025.
The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of Company’s website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.